CoChat

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial

Lewis, Sandra J., Moye, Lemuel A., Sacks, Frank M., Johnstone, David E., Timmis, Gerald, Mitchell, Jayne, Limacher, Marian, Kell, Sherron, Glasser, Stephen P., Grant, Jane, Davis, Barry R., Pfeffer, Marc A., Braunwald, Eugene · 1998 · Annals of Internal Medicine

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: A majority of all myocardial infarctions occur in patients who are 65 years of age or older and have average cholesterol levels, but little information is available on whether cholesterol lowering in such patients reduces the rate of recurrent cardiovascular disease. OBJECTIVE: To determine whether pravastatin reduces the rate of recurrent cardiovascular events in older patients. DESIGN: Subset analysis of a randomized, controlled trial. SETTING: 80 hospitals and affiliates in the United States and Canada. PATIENTS: 1283 patients aged 65 to 75 years who had had myocardial infarction and had a plasma total cholesterol level less than 6.2 mmol/L (240 mg/dL) and a low-density lipoprotein cholesterol level of 3.0 to 4.5 mmol/L (115 to 174 mg/dL). INTERVENTION: Pravastatin, 40 mg/d, or placebo. MEASUREMENTS: Five-year event rates of major coronary events (coronary death, nonfatal myocardial infarction, angioplasty, or bypass surgery) and stroke. RESULTS: Major coronary events occurred in 28.1% of placebo recipients and 19.7% of pravastatin recipients (difference, 9.0 percentage points [95% CI, 4 to 13 percentage points]; relative risk reduction, 32%; P < 0.001). Coronary death occurred in 10.3% of the placebo group and in 5.8% of the pravastatin group (difference, 4.6 percentage points [CI, 1.9 to 6.5 percentage points]; relative risk reduction, 45%; P = 0.004). Stroke incidence was 7.3% in the placebo group and 4.5% in the pravastatin group (absolute reduction, 2.9 percentage points [CI, 0.3 to 4.5 percentage points]; relative reduction, 40%; P = 0.03). The numbers of older patients needed to treat for 5 years were 11 (CI, 8 to 24) to prevent a major coronary event and 22 (CI, 15 to 53) to prevent a coronary death. For every 1000 older patients treated, 225 cardiovascular hospitalizations would be prevented compared with 121 hospitalizations in 1000 younger patients. CONCLUSIONS: In older patients with myocardial infarction and cholesterol levels in the average range, pravastatin is associated with a clinically important reduction in risk for major coronary events and stroke. Given the high cardiovascular event rate in older patients, the potential for absolute benefit in this age group is substantial.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-129-9-199811010-00002

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

See all 452

Metadata

Authors
Lewis, S. J., Moye, L. A., Sacks, F. M., Johnstone, D. E., Timmis, G., Mitchell, J., Limacher, M., Kell, S., Glasser, S. P., Grant, J., Davis, B. R., Pfeffer, M. A., & Braunwald, E.
Affiliations
For the CARE Investigators
Corresponding author
Lewis, Sandra J.
Venue
Annals of Internal Medicine
Published
1998-11-01
Volume
129
Issue
9
Pages
681-689
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2135171522
Cited by
427
References
43
Citations by year
2025: 1 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 7 · 2017: 5 · 2016: 12 · 2015: 14 · 2014: 11 · 2013: 21 · 2012: 12
FWCI
25.52
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
pravastatin, statins, myocardial infarction, older adults, recurrent cardiovascular events, coronary events, coronary death, stroke, cholesterol lowering, LDL cholesterol, total cholesterol, CARE trial, secondary prevention, number needed to treat, angioplasty, coronary artery bypass grafting, nonfatal myocardial infarction
MeSH terms
Aged, Anticholesteremic Agents, Cardiovascular Diseases, Cholesterol, Double-Blind Method, Female, Humans, Cholesterol, LDL, Male, Myocardial Infarction, Recurrence, Statistics as Topic, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. https://app.cochat.ai/papers/10.7326/0003-4819-129-9-199811010-00002
The paper
Lewis, S. J., Moye, L. A., Sacks, F. M., Johnstone, D. E., Timmis, G., Mitchell, J., Limacher, M., Kell, S., Glasser, S. P., Grant, J., Davis, B. R., Pfeffer, M. A., & Braunwald, E. (1998). Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-129-9-199811010-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.